Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents.
Riether C, Pabst T, Höpner S, Bacher U, Hinterbrandner M, Banz Y, Müller R, Manz MG, Gharib WH, Francisco D, Bruggmann R, van Rompaey L, Moshir M, Delahaye T, Gandini D, Erzeel E, Hultberg A, Fung S, de Haard H, Leupin N, Ochsenbein AF. Riether C, et al. Among authors: muller r. Nat Med. 2020 Sep;26(9):1459-1467. doi: 10.1038/s41591-020-0910-8. Epub 2020 Jun 29. Nat Med. 2020. PMID: 32601337 Clinical Trial.
inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice.
Ellegast JM, Rauch PJ, Kovtonyuk LV, Müller R, Wagner U, Saito Y, Wildner-Verhey van Wijk N, Fritz C, Rafiei A, Lysenko V, Dudkiewicz E, Theocharides AP, Soldini D, Goede JS, Flavell RA, Manz MG. Ellegast JM, et al. Among authors: muller r. Blood. 2016 Oct 27;128(17):2130-2134. doi: 10.1182/blood-2015-12-689356. Epub 2016 Aug 31. Blood. 2016. PMID: 27581357 Free PMC article.
Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor-refractory multiple myeloma.
Driessen C, Müller R, Novak U, Cantoni N, Betticher D, Mach N, Rüfer A, Mey U, Samaras P, Ribi K, Besse L, Besse A, Berset C, Rondeau S, Hawle H, Hitz F, Pabst T, Zander T. Driessen C, et al. Among authors: muller r. Blood. 2018 Nov 8;132(19):2097-2100. doi: 10.1182/blood-2018-05-851170. Epub 2018 Sep 20. Blood. 2018. PMID: 30237154 Free PMC article. Clinical Trial. No abstract available.
Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy.
Pabst T, Vey N, Adès L, Bacher U, Bargetzi M, Fung S, Gaidano G, Gandini D, Hultberg A, Johnson A, Ma X, Müller R, Nottage K, Papayannidis C, Recher C, Riether C, Shah P, Tryon J, Xiu L, Ochsenbein AF. Pabst T, et al. Among authors: muller r. Haematologica. 2023 Jul 1;108(7):1793-1802. doi: 10.3324/haematol.2022.281563. Haematologica. 2023. PMID: 36779592 Free PMC article. Clinical Trial.
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.
Ghilardi G, Pabst T, Jeker B, Müller R, Cairoli A, Müller AMS, Bargetzi M, Hitz F, Baldomero H, Heim D, Schmidt A, Rossi D, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg JR, Stussi G, Kleber M, Gerber B; Swiss Blood Stem Cell Transplantation Registry. Ghilardi G, et al. Among authors: muller r, muller ams. Bone Marrow Transplant. 2019 Jul;54(7):1029-1037. doi: 10.1038/s41409-018-0379-y. Epub 2018 Nov 2. Bone Marrow Transplant. 2019. PMID: 30390061 Clinical Trial.
5,382 results